Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Antares Pharma has announced that a second patent extension covering its proprietary Advanced Transdermal Delivery Gel System has been issued by the US Patent and Trademark Office.
Subscribe to our email newsletter
The Advanced Transdermal Delivery (ATD) Gel System is responsible for the enhanced bioavailability of Anturol (oxybutynin), Elestrin (estradiol), LibiGel (testosterone), the Nestorone and estradiol ATD contraceptive and JZP-7 the ropinirole formulation (partnered with Jazz Pharmaceuticals).
Dario Carrara, Antares Pharma’s senior vice president and managing director of the Pharmaceutical Group, said: “The issuance of this patent is an important achievement in the strengthening of company’s intellectual property portfolio. This second extension demonstrates the potential flexibility of our ATD system technology to accommodate difficult to deliver drugs for the treatment of conditions such as pain, migraines, nauseas and neuro-degenerative disorders.”